Yen-Chun Lu, Ph.D.’s Post

10/3/24: Syncona Limited : Resolution Therapeutics Raises £63.5 Million in Series B Financing | Appoints New Chair Use of proceeds from the Series B financing will support the clinical entry and development of RTX001, with a Phase I/II trial expected to start in Q4 CY2024. Following this financing, Resolution Therapeutics is funded to deliver data from this trial, anticipated in CY2026, a key value inflection point with the potential to drive significant NAV growth for Syncona. Proceeds will also be used to develop the company’s manufacturing platform, expand the pre-clinical pipeline, and further strengthen the management team, following several key recent appointments, including Dr Amir Hefni as CEO, Simon Ramsden as CFO and Dr Clifford A. Brass as CMO. Read the full scoop at https://lnkd.in/eG_3gs6D

#fundingalert 💼Company: SynOx Therapeutics 💰Funding: $75Million ⚡Round: Series B  👥Investors: Forbion, HealthCap, Bioqube Ventures, Jon Edwards, PhD, and Carlo Incerti. Founded in November 2020, SynOx Therapeutics Ltd.'s only goal is to develop emactuzumab for use in treating diffuse tenosynovial giant cell tumours (TGCT) and other conditions. With a solid track record of developing biopharma enterprises, SynOx has the support of a syndicate of investors. Biotech startup. The money will be used by the business to provide registrational Phase 3 clinical and CMC data for emactuzumab, a monoclonal antibody (mAb) that inhibits CSF-1(R) and may be the best in class for treating Tenosynovial Giant Cell Tumours (TGCT). Raymond Barlow, Hamina Patel, MB BCh MSc MRCPI, Broes Naeye, Sarah Clare, Sander Veltkamp. Read more - https://lnkd.in/gs-h6Kyd To share your startup story write us on - contact@startuprise.co.uk #SynOxTherapeutics #biopharma #Biotechstartup #funding #fundingnews #news #startupnews #news #startuprise

Iambic Therapeutics announced the closing of an oversubscribed $50 million extension to its Series B financing. The Series B extension was funded by new investors Mubadala Capital, Exor Ventures and the Qatar Investment Authority (QIA), and existing investors Abingworth, Illumina Ventures, Nexus Ventures, Coatue, and Tao Capital. The extension adds to an oversubscribed $100 million Series B that closed in October and was co-led by Ascenta Capital and Abingworth, joined by NVIDIA and others.    Iambic Therapeutics' physics-informed AI-driven discovery platform has enabled a pipeline of novel small molecule therapeutics, including IAM1363, a highly selective, brain-penetrant inhibitor of wild-type and oncogenic mutant HER2 proteins currently in Phase 1 studies, and IAM-C1, a potential first-in-class selective dual CDK2/4 inhibitor. Proceeds from a combined >$150M Series B financing will be used to broaden and accelerate Iambic's clinical and pre-clinical oncology programs.    Ron Mazumder Charles Lin Bill Rastetter     Read the full press release: https://lnkd.in/eQk6jD96    This news follows another exciting announcement earlier that Thomas Miller, CEO of Iambic Therapeutics, has received the EY Entrepreneur Of The Year® 2024 Pacific Southwest Award. See EY’s full press release here: https://lnkd.in/eUShge_T Way to go, Tom!    #partnernews #SeriesB #biotech #lifescience #MachineLearning #AI #DrugDiscovery #healthcare

It’s time to find out who bagged the biggest private biotech investments in June 2024! 💰 The biggest funding rounds went to the companies Formation Bio, ITM Isotope Technologies Munich SE, and Marea Therapeutics. 📈 Meanwhile, around the world, oncology and central nervous system players attracted the biggest funding rounds overall. 🌍 Read our latest article to find out more about biotech’s biggest private investments in June, as we break down the investments by location and funding type, and compare June’s fundraising to previous months. 💡 https://lnkd.in/dYvuBVt9 #biotechinvestments #oncologyresearch #biotechfunding #healthcareinnovation #investmenttrends #globalbiotech #lifesciences Santa Ana Bio, Inc. | Alzheon, Inc. | Preserving Future Memories | Bright Peak Therapeutics | iOnctura | InduPro | Exsilio Therapeutics | Elion Therapeutics | Enveda Biosciences | Iambic Therapeutics | Spur Therapeutics | āshibio, Inc | Adcytherix | Envisagenics | Vilya | Frontier Medicines | Augustine Therapeutics | GPN Vaccines

Biopharma Funding Activity May 20th-24th ‘24 2 newly launched companies and more funding events… Get these weekly → https://lnkd.in/gDdkUYb3 – 𝐏𝐫𝐢𝐯𝐚𝐭𝐞 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 – AltruBio Inc. 💸  Received an oversubscribed Series B financing of up to $225M led by BVF Partners LP, and other investors to support ongoing and planned Phase 2a and 2b clinical trials of immune checkpoint enhancer, ALTB-268, in ulcerative colitis. Pheon Therapeutics 💸  Completed a $120m Series B financing led by TCGX, with participation from BVF Partners and other investors. The funding will be used to further advance Pheon's differentiated ADC pipeline through clinical proof of concept for its first three assets in a wide range of solid tumors. SixPeaks Bio 💸  Launched with $110M funding: $30M in Series A led by Versant Ventures and $80M  non-dilutive financing from AstraZeneca. 𝐏𝐫𝐨𝐠𝐞𝐧𝐭𝐨𝐬 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 💸  Launched with $65M Series A financing led by Forbion to advance its multiple sclerosis program. Aktis Oncology 💸  Received $60M upfront cash payment for the collaboration in addition to an equity investment in Aktis by Lilly to generate novel tumor-targeting radiopharmaceuticals. – 𝐏𝐨𝐬𝐭-𝐈𝐏𝐎/𝐏𝐮𝐛𝐥𝐢𝐜 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 – Bicycle Therapeutics 🏦  Announced $555M private investment in public equity. Cytokinetics 🏦  Announced pricing of $500M stock offering. Dyne Therapeutics 🏦  Announced pricing of $325.5M public offering. Erasca, Inc.  🏦  Announced closing of $184M offering. Foghorn Therapeutics Inc. 🏦  Announced pricing of $110M direct offering and pre-funded warrants. --- 👋 I'm Dominic Vacchiano, Co-founder of BiopharmIQ by Amp. We provide biopharma data to help with your sales/BD activities. 📰 Each week we share clinical/regulatory/funding news in an easy-to-digest format. #biotech #biopharma

Private Biotech investment is on the steady rise reaching new highs in April with $3.1 billion raised that is surpassing previous three months activity according to Labiotech.eu report (https://lnkd.in/gUY2_xc7). In terms of geography, Europe and Asia-Pacific are trailing US. Among specific therapeutic areas Biotech companies developing Oncology assets are attracting largest investment that went solely to US and Asia-Pacific regions. This brings a question if European Biotech companies developing Oncology drugs face some unique challenges despite a very active recent trend of M&A. During 2023 there was high activity involving European based Biotechs with oncology pipeline. Interest in ADCs drove a licensing deal between Synaffix and MacroGenics, followed by the acquisition of Synaffix by Lonza. In addition, radiopharmaceutical Biotech ITM Isotope Technologies Munich raised one of the largest private investment rounds in European Biotech in 2023. In 2024 MorphoSys was acquired by Novartis, RedX Pharma was acquired by Jazz Pharmaceuticals, and Autolus Therapeutics was acquired by Bio NTech SE in February. Interesting to follow trends for Europe and see if there is influence of fragmented nature of the EU healthcare market making drug adoption prediction complex, possibly more risk-averse approach of EU-based buyers, as well as evolution of global reimbursement market on financial dynamics of the EU Biotech activity. #Biotech #Europe #US #Asia-pacific #M&A #private funding #therapeutic focus #oncology #ADC #radiopharmaceuticals

Cambridge biopharma company PhoreMost Ltd, has added $12 million to its Series B financing, bringing the total raised to over $50m. The additional investment was led by Parkwalk Advisors with participation from existing investors BGF, Dr Jonathan Milner, Amadeus Capital Partners and Astellas Venture Management (Astellas Pharma). The haul will support the progression of PhoreMost’s pipeline of novel degrader assets. Based at Howard Group’s Unity Campus hub, PhoreMost is unlocking the next generation of drug targets. It is focused on leveraging its SITESEEKER® target ID platform to enable novel ligase discovery. Since the closure of its previous Series B financing in 2021, the company has expanded drug discovery operations and advanced multiple next-generation degrader programmes through proof-of-concept studies following these discoveries. This new investment will enable pipeline progression of PhoreMost’s novel degrader programmes in oncology and inflammatory diseases towards preclinical development. The money also supports further deployment of the recently launched GlueSEEKER™ platform2, informing molecular glue design for unprecedented targets, and support the growth of new and existing pharma collaborations. PhoreMost CEO Dr Neil Torbett, said: “PhoreMost is at an incredibly exciting phase of development, where we are now progressing our high value oncology and inflammation degrader programmes towards preclinical studies.” Alastair Kilgour, Founder, Parkwalk Advisors, and Non-Executive Director, PhoreMost added: “The PhoreMost team has made excellent progress in developing novel therapeutic approaches within the field of targeted protein degradation, a modality that is set to deliver transformational outcomes for patients suffering with untreated conditions and revolutionise the future of medicine. We are excited to continue supporting both the leadership and scientific teams as they scale and improve the lives of millions.” Full article – https://lnkd.in/e58K4VZB

🚀🔬 It’s time to take a look at the biggest private biotech investments of July 2024! 💰 Last month, the companies Cardurion Pharmaceuticals, Beacon Therapeutics, and Third Arc Bio bagged the biggest investment rounds. 🎯 And, just as in June, oncology and central nervous system players attracted the biggest funding rounds overall. 🧠💉 📍Plus, in terms of location, North America and Europe also achieved the same amount of fundraising rounds as they did in June, with 15 and 11 respectively. 🌍💼 Read our latest article to find out more details! 🔍 https://lnkd.in/d4xze2x7 #biotech #investments #pharma #oncology #innovation #funding #biotech2024 #healthcare CatalYm GmbH | Scorpion Therapeutics | NGM Biopharmaceuticals | Myricx Bio | Asceneuron SA | Autobahn Therapeutics, Inc. | SciRhom | Confo Therapeutics | GRO Biosciences | AIRNA | SmartCella Holding AB | AusperBio | Rona Therapeutics | CellCentric | ReviR Therapeutics | LTZ Therapeutics

There were 21 biotech & pharma equity financings last week, topped by a $250M private placement. Below are the most newsworthy deals 👇   ➡️ PUBLIC ⬅️   🏆 Lexicon Pharmaceuticals, Inc. secured $250M in an oversubscribed private placement. The funds will support development of therapies for heart failure, neuropathic pain, and diabetes.   💎 Regulus Therapeutics completed an oversubscribed $100M private placement led by Adage Capital Partners LP and New Enterprise Associates (NEA). Regulus is advancing medicines targeting microRNAs.   🔥 Lexeo Therapeutics closed an oversubscribed $95M private placement co-led by Braidwell and Adage Capital Partners LP. Proceeds will fund clinical programs in cardiovascular disease and Alzheimer’s, with a runway into 2027.   👏 Skye Bioscience Inc. completed a $40M private placement to fund the expansion of obesity clinical trials and extend operations beyond 2026. Lead investors include Perceptive Advisors, Velan Capital, and Schonfeld Strategic Partners Fund LLC.   ➡️ PRIVATE ⬅️   👑 Tubulis GmbH completed a €128M Series B2 financing, co-led by EQT Life Sciences & Nextech Invest. The funds will expedite clinical trials for solid tumor ADCs, TUB-030 & TUB-040, and support US expansion.   💸 Zephyr AI closed a $111M Series A from investors including REVOLUTION GROWTH III LP and Eli Lilly and Company. The funds will enhance AI for precision medicine, targeting oncology and cardiometabolic diseases.   🚀 Relation secured $35M in seed financing led by DCVC and nVentures. Relation is advancing drug discovery for osteoporosis using computational approaches, machine learning, and single-cell multi-omics. 🎯 X-Therma Inc. completed an oversubscribed $22.4M Series B for its regenerative medicine and organ preservation platform. The funding will advance their XT-Thrive® and XT-ViVo® products, with FDA Breakthrough Device status for organ preservation.